ANS may bar Hapvida from double-digit premium hikes or cancellations affecting 947,000 plans pending review

Reuters2026/08/21 11:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Hapvida flagged a commercial review of loss-making or delinquent contracts covering 947,000 members, about 11% of its health portfolio.
Review is set to run contract-by-contract at renewal dates over the next 12 months, potentially affecting pricing or continuity for clients.
ANS was reported in the press to have issued a precautionary order to block double-digit price hikes or cancellations tied to the review.
Hapvida said it has not received any ANS notice or decision, requested a hearing, plans to provide technical and regulatory explanations.
No change to the 2Q26 outlook; Hapvida said it sees no undisclosed material fact because it has not been formally notified.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hapvida Participações e Investimentos SA published the original content used to generate this news brief on August 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

ANS may bar Hapvida from double-digit premium hikes or cancellations affecting 947,000 plans pending review

You may also like

Crypto prices